Anti-CD20 monoclonal antibody (rituximab) became the first monoclonal antibody approved for cancer treatment in 1997, and it could kill tumor cells by complement-dependent and antibody-dependent cytotoxicity. The gene discussed is MS4A1; the disease is neoplasm.